Has the FDA Raised the Vitruvias Thyroid Recall to Its Highest Risk Level?
As of September 24, 2026, the FDA has placed one lot of Vitruvias Therapeutics Thyroid Tablets, USP 30 mg, in Class I, the agency’s highest recall category. The recall started in August after testing found that the tablets could be superpotent, meaning they may contain more thyroid hormone activity than intended. That raises a practical […]







